403-33-8Relevant articles and documents
Absolute raman intensities of the carbonyl stretching band in para substituted methyl benzoates
Vanderheyden,Zeegers-Huyskens
, p. 1423 - 1428 (1989)
The absolute Raman intensities of the vC=0 band of para-substituted methyl benzoates have been measured in CCl4 solution at different excitation frequencies. The intensities depend on a preresonance Raman effect (PRRE) and are correlated with theoretical expressions which describe the dispersion of the Raman intensity as a function of the excitation frequency and the experimental UV frequencies of the compounds, in particular the π→π* 1La band. The Raman intensities free from PRRE are deduced by extrapolating the experimental values to a zero excitation frequency. These extrapolated intensities depend on the electron-donating character of the substituents and on the extent of the conjugated system. The depolarization ratio of the vC=0 band in methyl benzoates increases with the excitation energies. This ratio is higher for the para-substituted derivatives.
Androgen receptor inhibitor and application thereof
-
Paragraph 0273-0276, (2021/11/10)
The invention relates to the field of pharmacy, and particularly discloses an androgen receptor (AR) regulator combined with E3 ubiquitin ligase ligand or a salt thereof. Isomer and contains their pharmaceutical compositions.
GPR52 Antagonist Reduces Huntingtin Levels and Ameliorates Huntington's Disease-Related Phenotypes
Wang, Congcong,Zhang, Yu-Fang,Guo, Shimeng,Zhao, Quan,Zeng, Yanping,Xie, Zhicheng,Xie, Xin,Lu, Boxun,Hu, Youhong
, p. 941 - 957 (2020/11/30)
GPR52 is an orphan G protein-coupled receptor (GPCR) that has been recently implicated as a potential drug target of Huntington's disease (HD), an incurable monogenic neurodegenerative disorder. In this research, we found that striatal knockdown of GPR52 reduces mHTT levels in adult HdhQ140 mice, validating GPR52 as an HD target. In addition, we discovered a highly potent and specific GPR52 antagonist Comp-43 with an IC50 value of 0.63 μM by a structure-activity relationship (SAR) study. Further studies showed that Comp-43 reduces mHTT levels by targeting GPR52 and promotes survival of mouse primary striatal neurons. Moreover, in vivo study showed that Comp-43 not only reduces mHTT levels but also rescues HD-related phenotypes in HdhQ140 mice. Taken together, our study confirms that inhibition of GPR52 is a promising strategy for HD therapy, and the GPR52 antagonist Comp-43 might serve as a lead compound for further investigation.